# Remdesivir – COVID-19 – India (Repurposing Scan)

**Report ID:** REP-20251217-7d2fdd
**Generated At:** 2025-12-17T11:11:01.562514
**Format:** pdf

## Executive Summary

- Remdesivir, also known by its synonyms GS-5734 and Veklury, is recommended by authoritative guidelines such as WHO and NICE for treatment of hospitalized COVID-19 patients under specific conditions. Recent publications between 2019 and 2024 indicate clinical and case report studies on remdesivir use, including safety and treatment outcomes, particularly in special populations like patients with severe chronic kidney disease. Indian news sources report on regulatory approvals, local guideline issuance, supply challenges, and legal actions related to remdesivir use in COVID-19 management within India. This reflects ongoing monitoring and management of remdesivir use in the region in the COVID-19 pandemic context.

## Clinical Trials

### Summary

- Active trials: 3
- Completed trials: 2
- Phase distribution: Phase Observational (1) Phase Phase 1 (0) Phase Phase 2 (2) Phase Phase 3 (1) Phase Phase 4 (0)

### Highlights

- No Phase III trials identified in India

### Top Trials

| Trial ID | Title | Phase | Status | Locations | Start Date |
|---|---|---|---|---|---|
| NCT04610541 | Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and | Phase 3 | Active | Hungary | 2020-10-12 |

| Trial ID | Title | Phase | Status | Locations | Start Date |
|---|---|---|---|---|---|
| | Severe Covid-19 Patients | | | | |
| NCT04647695 | An Open-label Randomized Controlled Trial on Interferon β-1b and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 Infection | Phase 2 | Active | Hong Kong | 2020-11-20 |
| NCT04345419 | Remdesivir in COVID-19 Treatment: A Randomised Trial | Phase 2 | Completed | Egypt | 2020-06-16 |
| NCT04582266 | Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States | Observational | Completed | United States | 2021-03-31 |
| NCT04560231 | Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study | EARLY_Phase 1 | Active | Pakistan | 2020-06-01 |

# Guidelines and Literature

## Guidelines

- **WHO Guidelines:** Remdesivir is recommended for treatment of COVID-19 in hospitalized patients under specific conditions as per WHO guidance.
- **NICE Guidelines:** NICE recommends remdesivir as an antiviral treatment option for hospitalized COVID-19 patients requiring oxygen.

## Publications

- **PMID 39816292 (2024):**
- **PMID 39811032 (2024):**
- **PMID 39739156 (2025):**
- **PMID 39743047 (2025):**

# Repurposing Options

- **Targeted subgroup usage**
  Rationale: Remdesivir, also known by its synonyms GS-5734 and Veklury, is recommended by authoritative guidelines such as WHO and NICE for treatment of hospitalized COVID-19 patients under specific conditions. Recent publications between 2019 and 2024 indicate clinical and case report studies on remdesivir use, including safety and treatment outcomes, particularly in special populations like patients with severe chronic kidney disease. Indian news sources report on regulatory approvals, local guideline issuance, supply challenges, and legal actions related to remdesivir use in COVID-19 management within India. This reflects ongoing monitoring and management of remdesivir use in the region in the COVID-19 pandemic context.
  Evidence: WHO Guidelines, NICE Guidelines

# Risks and Gaps

- Limited late-stage clinical evidence
- Geography-specific data gaps for India

# References

- **Guideline:** WHO Guidelines — https://www.who.int/publications/guidelines
- **Guideline:** NICE Guidelines — https://www.nice.org.uk/guidance
- **Publication:** PMID:39816292 — https://pubmed.ncbi.nlm.nih.gov/39816292/
- **Publication:** PMID:39811032 — https://pubmed.ncbi.nlm.nih.gov/39811032/
- **Publication:** PMID:39739156 — https://pubmed.ncbi.nlm.nih.gov/39739156/
- **Publication:** PMID:39743047 — https://pubmed.ncbi.nlm.nih.gov/39743047/
- **Trial:** NCT04610541 — https://clinicaltrials.gov/study/NCT04610541
- **Trial:** NCT04647695 — https://clinicaltrials.gov/study/NCT04647695
- **Trial:** NCT04345419 — https://clinicaltrials.gov/study/NCT04345419
- **Trial:** NCT04582266 — https://clinicaltrials.gov/study/NCT04582266
- **Trial:** NCT04560231 — https://clinicaltrials.gov/study/NCT04560231

# Warnings

- **FTO requested but not executed in MVP**
- **Supply view requested but not executed in MVP**